GlassScriptPhysician profile
Catherine Badim
NPI 1518575232
$4,051.80
in general payments reported to CMS, 2019-2025
26 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 96% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $312 · 2023: $470 · 2024: $1,386 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.68 |
| Education | $126.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $528.99 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $476.94 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $448.19 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $390.86 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $380.09 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Madrigal Pharmaceuticals | $358.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $297.74 | 2022-2025 | Ibsrela |
| Pfizer INC. | $251.43 | 2022-2025 | |
| Lilly USA, LLC | $220.22 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $115.36 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $84.84 | 2023-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $74.93 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $66.87 | 2025 | Sucraid |
| Redhill Biopharma INC. | $56.91 | 2022-2024 | Talicia, Aemcolo |
| Dentsply Ih Ab | $52.76 | 2024 | Navina Rectal Catheter Set Regular |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $46.62 | 2022-2024 | Injectafer |
| Vapotherm INC | $31.56 | 2022 | |
| Boston Scientific Corporation | $30.10 | 2022 | |
| Evoke Pharma, INC. | $22.31 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.49 | 2024 | Clenpiq |
| Merck Sharp & Dohme LLC | $19.46 | 2023 | Dificid |
| Novo Nordisk INC | $18.45 | 2025 | Wegovy |
| Exact Sciences Corporation | $16.41 | 2025 | Cologuard Collection Kit |
| Vivus LLC | $16.02 | 2025 | Qsymia |
| Celltrion USA INC. | $15.19 | 2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Badim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.